Seattle Genetics

Seattle Genetics is a biotechnology company that is focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Its antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.
The Company also is advancing a deep pipeline of innovative therapies for blood cancers and solid tumors, including vadastuximab talirine (SGN-CD33A) an ADC in the pivotal phase 3 CASCADE clinical trial for acute myeloid leukemia (AML), enfortumab vedotin (ASG-22ME) for urothelial cancer under its collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer. Its programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.

Company Growth (employees)
Bothell, US
Size (employees)
890 (est)+18%
Seattle Genetics was founded in 1998 and is headquartered in Bothell, US

Key People at Seattle Genetics

Clay B. Siegall

Clay B. Siegall

Co-founder, President , CEO & Chairman
Todd E. Simpson

Todd E. Simpson

Eric Dobmeier

Eric Dobmeier

Chief Operating Officer
Vaughn Himes

Vaughn Himes

EVP, Process Sciences and Technical Operations
Chris Boerner

Chris Boerner

Executive Vice President, Commercial
Jonathan Drachman

Jonathan Drachman

Chief Medical Officer; EVP, Research and Development

Seattle Genetics Office Locations

Seattle Genetics has offices in Bothell, Zug and Washington
Bothell, US (HQ)
21717 30th Dr Se
Zug, CH
19 Dammstrasse, Suite 403–406

Seattle Genetics Data and Metrics

Seattle Genetics Financial Metrics

Seattle Genetics's revenue was reported to be $418.1 m in FY, 2016 which is a 24% increase from the previous period.

Revenue (FY, 2016)

418.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

390 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(140.1 m)

EBIT (FY, 2016)

(142.7 m)

Market capitalization (19-Jul-2017)

7.7 b

Closing share price (19-Jul-2017)


Cash (31-Dec-2016)

108.7 m
Seattle Genetics's current market capitalization is $7.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


269.3 m286.8 m336.8 m418.1 m

Revenue growth, %


Cost of goods sold

13.8 m17.5 m24.5 m28.2 m

Gross profit

255.5 m269.2 m312.3 m390 m

Gross profit Margin, %


R&D expense

379.3 m

General and administrative expense

139.2 m

Operating expense total

318.4 m346.6 m433.3 m560.9 m


(62.9 m)(77.4 m)(121 m)(142.7 m)

EBIT margin, %


Net Income

(62.5 m)(76.1 m)(120.5 m)(140.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


64.1 m56.9 m102.3 m108.7 m

Accounts Receivable

29.5 m39.2 m52.9 m61.9 m


27.1 m43.5 m57 m68.1 m

Current Assets

437.3 m408 m771.1 m734.6 m


40.8 m46.1 m49.6 m62.9 m

Total Assets

483.9 m459 m895.1 m838.4 m

Accounts Payable

120.7 m

Current Liabilities

99.2 m125.9 m134.3 m148.5 m

Non-Current Liabilities

154.5 m122.2 m74.9 m55.8 m

Total Liabilities

253.7 m248.1 m209.2 m204.3 m

Additional Paid-in Capital

960.4 m1 b1.6 b1.7 b

Retained Earnings

(730.3 m)(806.4 m)(926.9 m)(1.1 b)

Total Equity

230.2 m210.8 m685.9 m634.1 m

Financial Leverage

2.1 x2.2 x1.3 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.5 m)(76.1 m)(120.5 m)(140.1 m)

Depreciation and Amortization

8.6 m12.5 m14.5 m18 m

Accounts Receivable

3.9 m(9.7 m)(14 m)(9 m)


10.7 m(16 m)(14 m)(11.2 m)

Cash From Operating Activities

(1.1 m)(60 m)(133.2 m)(97 m)

Purchases of PP&E

(22.2 m)(17.2 m)(13.4 m)(27.8 m)

Cash From Investing Activities

(24.6 m)36.6 m(375.9 m)68.2 m

Cash From Financing Activities

35.2 m16.2 m554.4 m35.2 m
Y, 2016

Financial Leverage

1.3 x

Seattle Genetics Market Value History

Seattle Genetics Job Categories

Seattle Genetics Median Salaries

Source: 47 public H-1B filings from Seattle Genetics

Seattle Genetics Online and Social Media Presence

Seattle Genetics Company Life and Culture

You may also be interested in